Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

被引：78

作者：

Diana, Anna ^{[1
]}

Carlino, Francesca ^{[1
]}

Franzese, Elisena ^{[1
]}

Oikonomidou, Olga ^{[2
]}

Criscitiello, Carmen ^{[3
]}

De Vita, Ferdinando ^{[1
]}

Ciardiello, Fortunato ^{[1
]}

Orditura, Michele ^{[1
]}

机构：

[1] Luigi Vanvitelli Univ Campania, Sch Med, Div Med Oncol, Dept Precis Med, I-80131 Naples, Italy

[2] Univ Edinburgh, MRC Inst Genet & Mol Med, Edinburgh Ctr, Canc Res UK, Edinburgh EH4 2XR, Midlothian, Scotland

[3] European Inst Oncol IRCCS, IEO, I-20141 Milan, Italy

来源：

CANCERS | 2020年 / 12卷 / 04期

关键词：

triple negative breast cancer; neo-(adjuvant); biomarkers; PARP inhibitors; immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; HOMOLOGOUS RECOMBINATION DEFICIENCY; STANDARD NEOADJUVANT CHEMOTHERAPY; DOSE-DENSE CHEMOTHERAPY; PHASE-III TRIAL; HIGH-RISK; ADJUVANT CHEMOTHERAPY; ANDROGEN RECEPTOR; PLUS CHEMOTHERAPY;

D O I：

10.3390/cancers12040819

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.

引用

页数：25

共 118 条

[1]

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2]

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].

Alberro, J. A. ;

Ballester, B. ;

Deulofeu, P. ;

Fabregas, R. ;

Fraile, M. ;

Gubern, J. M. ;

Janer, J. ;

Moral, A. ;

de Pablo, J. L. ;

Penalva, G. ;

Puig, P. ;

Ramos, M. ;

Rojo, R. ;

Santesteban, P. ;

Serra, C. ;

Sola, M. ;

Solarnau, L. ;

Solsona, J. ;

Veloso, E. ;

Vidal, S. ;

Abe, O. ;

Abe, R. ;

Enomoto, K. ;

Kikuchi, K. ;

Koyama, H. ;

Masuda, H. ;

Nomura, Y. ;

Ohashi, Y. ;

Sakai, K. ;

Sugimachi, K. ;

Toi, M. ;

Tominaga, T. ;

Uchino, J. ;

Yoshida, M. ;

Coles, C. E. ;

Haybittle, J. L. ;

Moebus, V. ;

Leonard, C. F. ;

Calais, G. ;

Garaud, P. ;

Collett, V. ;

Davies, C. ;

Delmestri, A. ;

Sayer, J. ;

Harvey, V. J. ;

Holdaway, I. M. ;

Kay, R. G. ;

Mason, B. H. ;

Forbe, J. F. ;

Franci, P. A. .

LANCET ONCOLOGY, 2018, 19 (01) :27-39

[3]

Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer [J].

Barroso-Sousa, Romualdo ;

Jain, Esha ;

Kim, Dewey ;

Partridge, Ann H. ;

Cohen, Ofir ;

Wagle, Nikhil .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[4]

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[5]

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [J].

Bell, R. ;

Brown, J. ;

Parmar, M. ;

Toi, M. ;

Suter, T. ;

Steger, G. G. ;

Pivot, X. ;

Mackey, J. ;

Jackisch, C. ;

Dent, R. ;

Hall, P. ;

Xu, N. ;

Morales, L. ;

Provencher, L. ;

Hegg, R. ;

Vanlemmens, L. ;

Kirsch, A. ;

Schneeweiss, A. ;

Masuda, N. ;

Overkamp, F. ;

Cameron, D. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :754-760

[6]

Homologous recombination deficiency in triple negative breast cancer [J].

Belli, Carmen ;

Duso, Bruno Achutti ;

Ferraro, Emanuela ;

Curigliano, Giuseppe .

BREAST, 2019, 45 :15-21

[7]

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J].

Berry, DA ;

Cirrincione, C ;

Henderson, IC ;

Citron, ML ;

Budman, DR ;

Goldstein, LJ ;

Martino, S ;

Perez, EA ;

Muss, HB ;

Norton, L ;

Hudis, C ;

Winer, EP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1658-1667

[8]

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 [J].

Bertucci, Francois ;

Goncalves, Anthony .

CURRENT ONCOLOGY REPORTS, 2017, 19 (10)

[9]

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].

Bianchini, Giampaolo ;

Balko, Justin M. ;

Mayer, Ingrid A. ;

Sanders, Melinda E. ;

Gianni, Luca .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690

[10]

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents [J].

Birkbak, Nicolai J. ;

Wang, Zhigang C. ;

Kim, Ji-Young ;

Eklund, Aron C. ;

Li, Qiyuan ;

Tian, Ruiyang ;

Bowman-Colin, Christian ;

Li, Yang ;

Greene-Colozzi, April ;

Iglehart, J. Dirk ;

Tung, Nadine ;

Ryan, Paula D. ;

Garber, Judy E. ;

Silver, Daniel P. ;

Szallasi, Zoltan ;

Richardson, Andrea L. .

CANCER DISCOVERY, 2012, 2 (04) :366-375

← 1 2 3 4 5 6 7 8 9 10 →